# An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

> **NCT04486872** · PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

## Key facts

- **NCT ID:** NCT04486872
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-25
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-06-25
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486872, "An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04486872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*